Krassan Mitchell 4
4 · TherapeuticsMD, Inc. · Filed Feb 5, 2020
Insider Transaction Report
Form 4
Krassan Mitchell
EVP, Chief Strategy Officer
Transactions
- Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2020-02-03−194,297→ 489,658 totalExercise: $0.20From: 2013-09-01Exp: 2020-09-01→ Common Stock (194,297 underlying) - Exercise/Conversion
Common Stock
2020-02-03$0.19/sh+105,703$19,809→ 105,703 total - Exercise/Conversion
Common Stock
2020-02-03$0.20/sh+194,297$39,578→ 300,000 total - Sale
Common Stock
2020-02-03$2.26/sh−300,000$676,920→ 0 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2020-02-03−105,703→ 0 totalExercise: $0.19From: 2011-05-01Exp: 2020-05-01→ Common Stock (105,703 underlying)
Footnotes (2)
- [F1]The sales were made pursuant to the Reporting Person's 10b5-1 trading plan dated December 10, 2019 with respect to shares of common stock underlying options to purchase common stock that expire on or before September 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.285, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.